Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31130668 | 0.96 | CXCR4 (0.48) | PCSK9CXCR4OPRM1OPRD1PRMT1 | |
| SCHEMBL30517378 | 0.91 | PCSK9 (0.45) | PCSK9CXCR4OPRM1OPRD1PRMT1 | |
| SCHEMBL30517373 | 0.90 | CXCR4 (0.48) | PCSK9CXCR4IL23RCCKBRF13A1 | |
| SCHEMBL29417870 | 0.90 | CXCR4 (0.48) | PCSK9CXCR4IL23RCCKBRF13A1 | |
| SCHEMBL30517375 | 0.88 | PRMT1 (0.51) | PCSK9OPRM1OPRD1PRMT1KMT2A | |
| SCHEMBL30517354 | 0.87 | CXCR4 (0.45) | PCSK9CXCR4OPRM1OPRD1PRMT1 | |
| SCHEMBL30517386 | 0.86 | CXCR4 (0.48) | CXCR4OPRD1IL23RF13A1TGM2 | |
| SCHEMBL30517370 | 0.85 | PCSK9 (0.47) | PCSK9CXCR4IL23RKEAP1CCKBR | |
| SCHEMBL30517372 | 0.85 | KISS1R (0.42) | PCSK9CXCR4OPRM1OPRD1PRMT1 | |
| SCHEMBL30517344 | 0.85 | KISS1R (0.42) | PCSK9CXCR4OPRM1OPRD1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | TST, PTMS, CTH | PCSK9 2708/4885CXCR4 2101/4885OPRM1 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.